ABL Texcell Diagnostics (formerly ABL Diagnostics) specializes in the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases (AIDS, viral hepatitis and tuberculosis) by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. Export accounts for 69.7% of net sales.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-10-30	€2.420	+7.08%	8,144
26-10-29	€2.260	+0.89%	7,900
26-10-28	€2.240	-6.67%	12,615
26-10-27	€2.400	0.00%	5,894
26-10-26	€2.400	+0.84%	382

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ABL Texcell Diagnostics

Company calendar

Real-time Euronext Paris 10:21:35 2026-10-30 am EDT			5-day change	1st Jan Change
2.420 ^EUR	+7.08%		+1.68%	-19.33%

Oct. 21	ABL Texcell Diagnostics Ends Proposed Acquisition of Vela's US, Singapore Operations	MT
Oct. 19	ABL Texcell Diagnostics SA cancelled to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI

Market Cap	36.32M 40.55M 33.5M 30.32M 56.7M 3.86B 57.61M 400M 159M 2.02B 152M 149M 6.4B	P/E 2024	123x	P/E 2025	50x
Enterprise Value	37.25M 41.59M 34.37M 31.1M 58.15M 3.96B 59.09M 410M 164M 2.07B 156M 153M 6.56B	EV / Sales 2024	7,098,474x	EV / Sales 2025	6,185,843x
Free-Float	6.2%	Yield 2024	2.03%	Yield 2025	3.67%

Markets		Quality
Euronext Paris	ABLD	Real-time
CBOE	0OPO	Real-time
CBOE	FAUVp	Real-time
Deutsche Boerse AG	9BK0	Delayed
Börse Stuttgart	9BK0	Delayed

Oct. 21	ABL Texcell Diagnostics Ends Proposed Acquisition of Vela's US, Singapore Operations	MT
Oct. 19	ABL Texcell Diagnostics SA cancelled to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI
Oct. 12	ABL Texcell Diagnostics to Acquire French Biotech Company IntegraGen	MT
Oct. 11	ABL Diagnostics Société anonyme completed the acquisition of Business operations and assets of IntegraGen SA for ?0.1 million.	CI
Oct. 01	ABL Diagnostics Revises Revenue Guidance for the Financial Year 2026	CI
Sep. 22	ABL Texcell Diagnostics Signs LoI to Acquire Vela's US, Singapore Operations	MT
Sep. 20	ABL Texcell Diagnostics SA signed a letter of intent to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI
Sep. 18	ABL Diagnostics Shareholders Approve Name Change; Euronext Paris Listing to Remain	MT
Sep. 17	ABL Diagnostics Société anonyme has Changed its Name to ABL Texcell Diagnostics	CI
Sep. 11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
Sep. 11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
Sep. 11	Abionyx Pharma Partners With ABL Diagnostics Division for Viral Safety Testing of CER-001	MT
Sep. 10	Abionyx Pharma Enters into Strategic Partnership with TEXCELL (Abl Diagnostics) for Viral Safety and Clearance of Biologics	CI

ABL Texcell Diagnostics Stock

Stocks

ABLD

FR001400AHX6

Medical Equipment, Supplies & Distribution

Valuation: ABL Texcell Diagnostics

Chart: ABL Texcell Diagnostics

Latest news: ABL Texcell Diagnostics

Press Releases: ABL Texcell Diagnostics

News in other languages: ABL Texcell Diagnostics

Quotes and Performance

Price Extremes

Managers and Directors: ABL Texcell Diagnostics

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Oct. 20	ABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of Intent	BU
Oct. 19	ABL Texcell Diagnostics Strengthens the Foundations of a Stable Shareholder Base and Pursues Its Growth Strategy	BU
Oct. 16	ABL Texcell Diagnostics: Notice of Appeal by the Public Prosecutor Regarding the IntegraGen Transfer Judgment	BU
Oct. 12	ABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen’s Assets and Operations	BU
Oct. 08	ABL Texcell Diagnostics Announces Availability of All Invest Securities Research Flash Note #8	BU

Oct. 21	Bourse : EssilorLuxottica qui rit, Michelin, Eurofins et Carrefour qui pleurent
Oct. 21	SpaceX et Super Micro en pompiers de la tech
Oct. 20	ABL TEXCELL DIAGNOSTICS ANNONCE LA RÉSILIATION DE LA LETTRE D’INTENTION RELATIVE À VELA DIAGNOSTICS
Oct. 19	ABL TEXCELL DIAGNOSTICS RENFORCE LES CONDITIONS D’UN ACTIONNARIAT STABLE ET POURSUIT SA STRATÉGIE DE CROISSANCE
Oct. 16	ABL TEXCELL DIAGNOSTICS : DÉCLARATION D’APPEL DU MINISTÈRE PUBLIC RELATIVE AU JUGEMENT DE CESSION D’INTEGRAGEN

1 day	+6.19%
1 week	+0.84%
Current month	+7.14%
1 month	+7.14%
3 months	-0.83%
6 months	-0.83%
Current year	-20.00%

1 week	2.18	2.52
1 month	2.1	2.6
Current year	2.1	5
1 year	2.1	5
3 years	2.1	9.7
5 years	1.99	26
10 years	1.28	26

Director	Title	Age	Since
Noemie Sadoun CHM	Chairman	-	-
Laure Raffaelli BRD	Director/Board Member	-	-
Deborah Szafir BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/28/26	Advanced Biological Laboratories SA	Sell	Company	-60,000	0.3723%
7/20/26	Advanced Biological Laboratories SA	Sell	Company	-65,616	0.4072%
7/6/26	Advanced Biological Laboratories SA	Sell	Company	-62,308	0.3867%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABL TEXCELL DIAGNOSTICS	+6.19%	+0.84%	-46.43%	-75.26%	40.55M
ABBOTT LABORATORIES	+1.88%	+2.01%	-15.96%	+12.62%	181B
STRYKER CORPORATION	+2.55%	+1.52%	-15.65%	+19.03%	120B
MEDTRONIC PLC	+2.46%	+0.54%	+5.87%	+39.87%	119B
ESSILORLUXOTTICA	+4.49%	+2.76%	-41.72%	+10.65%	91.44B
CENCORA, INC.	+1.91%	-2.35%	-0.79%	+76.15%	63.07B
HOYA CORPORATION	-0.46%	+0.42%	+8.19%	+82.97%	55.8B
BECTON, DICKINSON AND COMPANY	+1.63%	-1.04%	+9.27%	-21.17%	54.03B
IDEXX LABORATORIES, INC.	+2.32%	+1.63%	-8.23%	+47.17%	45.38B
ALCON INC.	+1.62%	+3.11%	0.00%	-5.41%	34.37B
Average	+1.15%	-0.07%	-10.55%	+18.66%	76.35B
Weighted average by Cap.	+0.13%	+0.76%	-9.62%	+26.87%

	2024	2025
Net sales	5.87 6.55 5.41 4.9 9.16 624.02 9.31 64.6 25.77 326.58 24.59 24.07 1.03K	7.97 8.89 7.35 6.65 12.44 846.88 12.64 87.67 34.98 443.22 33.38 32.66 1.4K
Net income	285K 318K 263K 238K 445K 30.32M 452K 3.14M 1.25M 15.87M 1.19M 1.17M 50.26M	987K 1.1M 910K 824K 1.54M 105M 1.57M 10.86M 4.33M 54.9M 4.13M 4.05M 174M
Net Debt	2.02M 2.26M 1.87M 1.69M 3.16M 215M 3.21M 22.28M 8.89M 113M 8.48M 8.3M 357M	933K 1.04M 860K 779K 1.46M 99.16M 1.48M 10.27M 4.1M 51.89M 3.91M 3.82M 164M